Screening Novel Agent Combinations to Expedite CTCL Therapeutic Development

Cutaneous T-cell lymphoma (CTCL) is a group of non-Hodgkin lymphomas of skin-homing malignant T lymphocytes. In advanced stages, CTCL is incurable and often fatal (Arulogun et al., 2008), and blood involvement portends a poorer outcome (Agar et al., 2010). Overall response rates to systemic therapies are 30–50% and generally not durable. High-throughput screening has emerged as a rapid method for identification and prioritization of novel therapeutic compounds. Analysis of natural compounds and agents in ongoing clinical trials may accelerate opportunities for drug repurposing, synergy testing, and preclinical assessment for CTCL therapeutic potential.

Source link

Related posts

This is a great resource to learn the basics and beyond regarding Dermoscopy


What causes an itchy stomach?


Holiday Day of Beauty, December 5, 2020


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy